Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals significant financial strain with increasing net losses and operational costs, despite a rise in cash reserves. The absence of a share repurchase program and unclear management responses during the Q&A further contribute to uncertainty. While there is optimism around the RP1 launch and regulatory progress, the lack of specific revenue guidance and potential commercial launch risks weigh negatively. Overall, the financial performance and operational challenges suggest a negative sentiment, likely leading to a stock price decline between -2% to -8%.
Key Financial Performance
Cash and Cash Equivalents $483.8 million (up from $420.7 million), an increase of $63.1 million year-over-year due to effective capital management.
Research and Development Expenses $54 million for Q4 2025 (up from $42.6 million), an increase of $11.4 million year-over-year primarily due to increased personnel-related costs and consulting expenses.
Total Research and Development Expenses for Fiscal Year $189.4 million (up from $175 million), an increase of $14.4 million year-over-year attributed to scaling operations for commercial launch.
Selling, General and Administrative Expenses $25.4 million for Q4 2025 (up from $16.2 million), an increase of $9.2 million year-over-year due to expanded operational activities.
Total Selling, General and Administrative Expenses for Fiscal Year $72.2 million (up from $59.8 million), an increase of $12.4 million year-over-year driven by increased personnel and operational costs.
Net Loss $74.1 million for Q4 2025 (up from $55.1 million), an increase of $19 million year-over-year reflecting higher operational expenses.
Total Net Loss for Fiscal Year $247.3 million (up from $215.8 million), an increase of $31.5 million year-over-year primarily due to increased R&D and SG&A expenses.
Stock-Based Compensation Expenses (R&D) $4.5 million for Q4 2025 (up from previous year), reflecting increased personnel costs.
Stock-Based Compensation Expenses (SG&A) $3.8 million for Q4 2025 (up from previous year), reflecting increased personnel costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Product Launch: Replimune is preparing for the potential approval and launch of RP1, an oncolytic immunotherapy for advanced melanoma patients who have previously received anti-PD-1 treatment.
Pipeline Development: Updates on RP2 and the RPX platform were discussed, focusing on potential benefits for patients beyond skin cancer.
Market Opportunity: Approximately 13,000 patients progress on or after PD-1 treatment annually in the U.S., with about 80% eligible for RP1.
Commercial Strategy: Replimune has identified roughly 350 key accounts that treat half of the melanoma population, focusing on targeted launch efforts.
Manufacturing Capacity: The U.S. manufacturing facility has produced commercial inventory to support the RP1 launch and has capacity for long-term global demand.
Commercial Infrastructure: The customer-facing team has been built out to approximately 60 people, focusing on demand generation and support.
Regulatory Progress: RP1 has been recognized as a breakthrough therapy with priority review and a PDUFA date of July 22, 2025.
Collaboration Strategy: Collaboration between oncologists and interventional radiologists is emphasized for the administration of RP1.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Earnings Expectations: Replimune Group, Inc. missed earnings expectations with a reported EPS of $-0.82, compared to expectations of $-0.75.
Regulatory Risks: The company faces risks associated with regulatory approval processes, particularly as they approach the PDUFA date for RP1.
Market Conditions: Changes in market conditions could impact the company's business activities and the potential success of RP1.
Research and Development Challenges: Difficulties associated with research and development may affect the progress and success of their product candidates.
Financial Performance: The company reported a net loss of $74.1 million for Q4 and $247.3 million for the fiscal year, indicating financial strain.
Operational Costs: Increased research and development expenses, primarily due to personnel-related costs, may pose challenges to financial stability.
Commercial Launch Risks: The successful launch of RP1 is contingent on various factors, including prescriber adoption and market competition.
Supply Chain Challenges: The company must ensure a reliable supply chain for the production and distribution of RP1 to meet anticipated demand.
Economic Factors: Economic conditions may influence the overall healthcare market and the company's ability to achieve its financial goals.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Regulatory Progress: RP1 recognized as a breakthrough therapy with priority review and a PDUFA date of July 22, 2025.
Clinical Trials: Ignite 3 confirmatory study underway with a primary endpoint of overall survival, with over 100 sites planned globally.
Commercial Readiness: U.S. manufacturing facility has produced commercial inventory to support RP1 launch.
Pipeline Development: Focus on RP2 and RPX for potential treatment beyond skin cancer.
Collaboration: Collaboration between oncologists and interventional radiologists to enhance treatment delivery.
Cash Runway: Current cash and equivalents of $483.8 million expected to fund operations into Q4 2026.
R&D Expenses: R&D expenses for Q4 2025 were $54 million, up from $42.6 million in Q4 2024.
Net Loss: Net loss of $74.1 million for Q4 2025, compared to $55.1 million in Q4 2024.
Commercial Opportunity: Estimated 13,000 patients progress on or after PD-1 treatment annually in the U.S., with 80% eligible for RP1.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What sort of medical education work are you going to be doing at ASCO ahead of the launch of RP1?
A:We’ve got a busy ASCO coming up with important posters showing response rates for injecting superficial lesions versus visceral lesions, and data on biomarker biodistribution and safety.
Q:Can you give us some color around your expectations for the launch trajectory?
A:We anticipate broad and rapid adoption across hospitals, with 150 of our top accounts trained on tumor injections by launch.
Q:What would be your NCCN listing strategy to potentially expand to some other subgroup?
A:We will submit data for NCCN listing once we have publication, and will evaluate future indications based on data.
Q:Can you discuss the impact you’re seeing from the recent regulatory changes and provide any color on recent FDA interactions?
A:We received breakthrough designation and submitted our BLA, with consistent engagement from the FDA and no impediments to our July 22 PDUFA.
Q:Can you discuss the translation of response rate into metrics like PFS and OS?
A:We’ve seen around 1/3 of patients achieve durable responses, with a median duration of over 20 months, PFS of around 4 months, and over 55% of patients alive at 3 years.
Q:Could you just talk to your experience to date with the IGNYTE3 trial?
A:We expect the trial to take a couple of years to complete enrollment, focusing on U.S. sites due to the upcoming PDUFA.
Q:Can you talk about your expectations on the potential label or label discussions for RP1?
A:We expect the label to reflect the broad population enrolled in IGNYTE.
Q:Can you talk about how you’re planning for manufacturing resiliency?
A:We have a facility designed for RP1 and anticipate sufficient inventory for a rapid launch.
Q:What are the gating factors that exist between now and the due date?
A:We completed our late cycle meeting and inspections, and feel well positioned with no bottlenecks towards our July 22 PDUFA.
Q:What feedback have you received from the FDA regarding manufacturing?
A:We have completed inspections and received formal feedback, which should not provide a bottleneck towards our PDUFA.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding specific revenue guidance and the exact details of the NCCN listing strategy for future indications.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Group Inc
Inc expectation
Transcript Group
expectation Financial
recording today
today obligation
REPL Transcript
Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript
Unknown5-23
The earnings call reveals significant financial strain with increasing net losses and operational costs, despite a rise in cash reserves. The absence of a share repurchase program and unclear management responses during the Q&A further contribute to uncertainty. While there is optimism around the RP1 launch and regulatory progress, the lack of specific revenue guidance and potential commercial launch risks weigh negatively. Overall, the financial performance and operational challenges suggest a negative sentiment, likely leading to a stock price decline between -2% to -8%.
Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript
Unknown5-22
The earnings call presents a mixed picture. Financial performance shows a net loss increase and rising expenses, which is negative. However, cash reserves increased, indicating good capital management. Product development updates, such as breakthrough designation and consistent FDA engagement, are positive. However, management avoided revenue guidance, creating uncertainty. The Q&A reveals a broad adoption expectation and manufacturing readiness, but concerns about supply chain challenges and unclear market strategies persist. Overall, the sentiment is balanced, leading to a neutral prediction.
Replimune (REPL) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
Neutral1-12
REPL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
